Načítá se...
Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
Immune checkpoint inhibitors (CPIs) have radically changed outcomes for patients diagnosed with metastatic melanoma globally in the last 10 years, based on evidence of overall survival (OS) benefits generated from international randomised controlled trials (RCTs). Since RCTs do not always reflect re...
Uloženo v:
| Vydáno v: | Int J Cancer |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7821238/ https://ncbi.nlm.nih.gov/pubmed/32838478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33266 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|